Literature DB >> 19531639

Frontiers: PED/PEA-15, a multifunctional protein controlling cell survival and glucose metabolism.

Francesca Fiory1, Pietro Formisano, Giuseppe Perruolo, Francesco Beguinot.   

Abstract

PED/PEA-15 is a 15-kDa ubiquitously expressed protein implicated in a number of fundamental cellular functions, including apoptosis, proliferation, and glucose metabolism. PED/PEA-15 lacks enzymatic function and serves mainly as a molecular adaptor. PED/PEA-15 is an endogenous substrate for protein kinase C (PKC), calcium/calmodulin-dependent protein kinase II (CAM kinase II), and Akt. In particular, PKC phosphorylates PED/PEA-15 at Ser(104) and CAM kinase II or Akt at Ser(116), modifying its stability. Evidence obtained over the past 10 years has indicated that PED/PEA-15 regulates cell survival by interfering with both intrinsic and extrinsic apoptotic pathways. In addition, it may also control cell proliferation by interfering with ERK1/2-mediated pathways. Indeed, PED/PEA-15 has been identified as an ERK1/2 interactor, which modifies its subcellular localization and targeting to a specific subset of substrates. Increased PED/PEA-15 levels may affect tumorigenesis and cancer progression as well as sensitivity to anticancer agents. Moreover, PED/PEA-15 affects astrocyte motility and increases susceptibility to skin carcinogenesis in vivo. PED/PEA-15 expression is regulated at the transcriptional and the posttranslational levels. Increased PED/PEA-15 expression has been identified in individuals with type 2 diabetes early during the natural history of the disease. Evidence generated over the past 10 years indicated that this defect contributes to altering glucose tolerance by impairing insulin action and insulin secretion and might play a role in the development of diabetes-associated neurological disorders. Strategies are being devised to target key signaling events in PED/PEA-15 action aimed at improving glucose tolerance and at facilitating cancer cell death.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19531639     DOI: 10.1152/ajpendo.00228.2009

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  37 in total

1.  Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Postmenopausal Women.

Authors:  Carol J Fabian; Bruce F Kimler; Teresa A Phillips; Jennifer L Nydegger; Amy L Kreutzjans; Susan E Carlson; Brandon H Hidaka; Trina Metheny; Carola M Zalles; Gordon B Mills; Kandy R Powers; Debra K Sullivan; Brian K Petroff; Whitney L Hensing; Brooke L Fridley; Stephen D Hursting
Journal:  Cancer Prev Res (Phila)       Date:  2015-08-14

2.  Validation of mouse phosphoprotein enriched in astrocyte 15 (mPEA15) expressing transgenic pig as a potential model in diabetes translational research.

Authors:  Bala Murali Krishna Vasamsetti; Hyun-Mi Kim; Kyung-Woon Kim; Seunghoon Lee; Keon Bong Oh; Sung-June Byun; Hak-Jae Chung; Seongsoo Hwang; Jae-Seok Woo; Byong-Chul Yang; Hwi-Cheul Lee
Journal:  3 Biotech       Date:  2020-01-07       Impact factor: 2.406

3.  Preliminary data on effects of metformin on PED/PEA-15 cellular levels in obese women with polycystic ovary syndrome.

Authors:  S Savastano; R Valentino; G Pizza; A De Rosa; F Orio; F Passaretti; P Formisano; G Lombardi; F Beguinot; A Colao
Journal:  J Endocrinol Invest       Date:  2010 Jul-Aug       Impact factor: 4.256

Review 4.  TRAIL-mediated signaling in prostate, bladder and renal cancer.

Authors:  Christina Voelkel-Johnson
Journal:  Nat Rev Urol       Date:  2011-06-14       Impact factor: 14.432

5.  PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma.

Authors:  Joanna E Gawecka; Dirk Geerts; Jan Koster; Maisel J Caliva; Florian J Sulzmaier; John Opoku-Ansah; Randal K Wada; André S Bachmann; Joe W Ramos
Journal:  Int J Cancer       Date:  2012-01-31       Impact factor: 7.396

6.  Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Premenopausal Women.

Authors:  Carol J Fabian; Bruce F Kimler; Teresa A Phillips; Jessica A Box; Amy L Kreutzjans; Susan E Carlson; Brandon H Hidaka; Trina Metheny; Carola M Zalles; Gordon B Mills; Kandy R Powers; Debra K Sullivan; Brian K Petroff; Whitney L Hensing; Brooke L Fridley; Stephen D Hursting
Journal:  Cancer Prev Res (Phila)       Date:  2015-10

7.  Bisphosphorylated PEA-15 sensitizes ovarian cancer cells to paclitaxel by impairing the microtubule-destabilizing effect of SCLIP.

Authors:  Xuemei Xie; Chandra Bartholomeusz; Ahmed A Ahmed; Anna Kazansky; Lixia Diao; Keith A Baggerly; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Mol Cancer Ther       Date:  2013-03-29       Impact factor: 6.261

8.  Association of the breast cancer antiestrogen resistance protein 1 (BCAR1) and BCAR3 scaffolding proteins in cell signaling and antiestrogen resistance.

Authors:  Yann Wallez; Stefan J Riedl; Elena B Pasquale
Journal:  J Biol Chem       Date:  2014-02-28       Impact factor: 5.157

9.  Presenilin1/γ-secretase protects neurons from glucose deprivation-induced death by regulating miR-212 and PEA15.

Authors:  Qian Huang; Georgios Voloudakis; Yimin Ren; Yonejung Yoon; Emily Zhang; Yuji Kajiwara; Zhiping Shao; Zhao Xuan; Denis Lebedev; Anastasios Georgakopoulos; Nikolaos K Robakis
Journal:  FASEB J       Date:  2017-08-30       Impact factor: 5.191

10.  A pilot study comparing protein expression in different segments of the normal colon and rectum and in normal colon versus adenoma in patients with Lynch syndrome.

Authors:  Chongjuan Wei; Jinyun Chen; Mala Pande; Patrick M Lynch; Marsha L Frazier
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-21       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.